ABSTRACT
BACKGROUND: The epidemiology, morbidity, and burden of the disease related to airway sequelae associated with invasive mechanical ventilation (IMV) in the context of the COVID-19 pandemic remain unclear. OBJECTIVE: This scoping review aims to summarize the current knowledge regarding airway sequelae after severe SARS-CoV2 infection. This knowledge will help guide research endeavors and decision-making in clinical practice. METHODS: This scoping review will include participants of all genders and no particular age group who developed post-COVID airway related complication will be excluded. No exclusion criteria will be applied from country, language or document type. The information source will include analytical observational, observational studies. Unpublished data will not be completely covered as grey literature will be covered. A total of 2 independent reviewers will participate in the process of screening, selection, and data extraction, and the whole process will be performed blindly. Conflict between reviewers will be solve through discussion and additional reviewer. Results will be reported by using descriptive statistics and information will be displayed on RedCap. RESULTS: The literature search was conducted in May 2022 in in the following databases; PubMed, EMBASE, SCOPUS, Cochrane Library, LILACS and Grey literature to identify observational studies; a total of 738 results were retrieved. The scoping review will be finished by March-2023. CONCLUSIONS: This scoping review will describe current knowledge on the most frequently encountered laryngeal and/or tracheal sequelae in patients exposed to mechanical ventilation due to SARS-CoV-2 infection. This scoping review will find the incidence of airway sequelae post-COVID19 and the most common sequelae such as; airway granuloma, vocal fold paralysis, and airway stenoses. Future studies should evaluate the incidence of these disorders. INTERNATIONAL REGISTERED REPORT: PRR1-10.2196/41811.
ABSTRACT
INTRODUCTION: Continuous subcutaneous insulin infusion (CSII) has emerged as a potential solution for diabetes management during the pandemic, as it reduces the need for in-person visits and allows for remote monitoring of patients. Telemedicine has also become increasingly important in the management of diabetes during the pandemic, as it allows healthcare providers to provide remote consultations and support. Here, we discuss the implications of this approach for diabetes management beyond the pandemic, including the potential for increased access to care and improved patient outcomes. METHODS: We performed a longitudinal observational study between 1 March 2020 and 31 December 2020 to evaluate glycemic parameters in diabetic patients with CSII in a telehealth service. Glycemic parameters were time in range (TIR), time above range, time below range, mean daily glucose, glucose management indicator (GMI), and glycemic variability control. RESULTS: A total of 36 patients were included in the study, with 29 having type 1 diabetes and 6 having type 2 diabetes. The study found that the proportion of patients achieving target glucose variability and GMI remained unchanged during follow-up. However, in patients with type 2 diabetes, the time in target range increased from 70% to 80%, and the time in hyperglycemia decreased from 2% to 0%. CONCLUSIONS: The results of this study suggest that telemedicine is a strategy for maintaining glycemic control in patients using CSII. However, the lack of access to the internet and adequate telemonitoring devices make it difficult to use on a large scale in emerging countries like ours.